Anjan Thakurta

5.7k total citations · 1 hit paper
100 papers, 2.5k citations indexed

About

Anjan Thakurta is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Anjan Thakurta has authored 100 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Hematology, 79 papers in Molecular Biology and 31 papers in Oncology. Recurrent topics in Anjan Thakurta's work include Multiple Myeloma Research and Treatments (80 papers), Protein Degradation and Inhibitors (55 papers) and Peptidase Inhibition and Analysis (19 papers). Anjan Thakurta is often cited by papers focused on Multiple Myeloma Research and Treatments (80 papers), Protein Degradation and Inhibitors (55 papers) and Peptidase Inhibition and Analysis (19 papers). Anjan Thakurta collaborates with scholars based in United States, United Kingdom and France. Anjan Thakurta's co-authors include Jian Kang, Anita K. Gandhi, Michael Amatangelo, Rajesh Chopra, Hervé Avet‐Loiseau, Anke Klippel, Yuhong Ning, Courtney G. Havens, Erin Flynt and Mehmet Samur and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

Anjan Thakurta

93 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 ^CRBN

2013 457 citations Anita K. Gandhi, Jian Kang et al. British Journal of Haematology profile →

Peers

Countries citing papers authored by Anjan Thakurta

Since Specialization

Citations

This map shows the geographic impact of Anjan Thakurta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anjan Thakurta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anjan Thakurta more than expected).

Fields of papers citing papers by Anjan Thakurta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anjan Thakurta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anjan Thakurta. The network helps show where Anjan Thakurta may publish in the future.

Co-authorship network of co-authors of Anjan Thakurta

This figure shows the co-authorship network connecting the top 25 collaborators of Anjan Thakurta. A scholar is included among the top collaborators of Anjan Thakurta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anjan Thakurta. Anjan Thakurta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis 2025 ·Blood Advances ·(unknown), (unknown), Christopher Butler, Karthik Ramasamy, Anjan Thakurta, David A. Clifton, Lei Clifton	0
2	Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma 2024 ·Cell Reports Medicine ·Oliver Van Oekelen, Michael Amatangelo, Manman Guo, Bhaskar Upadhyaya, Adam P. Cribbs, Geoff Kelly, Manishkumar Patel, Seunghee Kim‐Schulze, Erin Flynt, Alessandro Laganà, Sarah Gooding, Miriam Mérad, (unknown), William E. Pierceall, Udo Oppermann, Anjan Thakurta, Samir Parekh	7
3	High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma 2023 ·Blood ·Mehmet Samur, Marco Roncador, Anıl Aktaş Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphaël Szalat, Masood A. Shammas, Adam S. Sperling, Paul G. Richardson, Florence Magrangeas, Stéphane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Giovanni Parmigiani, Kenneth C. Anderson, Hervé Avet‐Loiseau, Nikhil C. Munshi	22
4	Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients 2023 ·Blood ·Gaurav Agarwal, (unknown), (unknown), (unknown), Lisa Ferguson, (unknown), Jaimal Kothari, Naser Ansari‐Pour, Sally Moore, Eileen M. Boyle, Udo Oppermann, Karthik Ramasamy, Angela Hamblin, Anjan Thakurta, Sarah Gooding	1
5	Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML‐001 trial 2023 ·British Journal of Haematology ·Daniel L. Menezes, Wendy L. See, Alberto Risueño, (unknown), Jae K. Lee, Johnny Ma, (unknown), Thomas Prébet, Barry Skikne, C.L. Beach, Anjan Thakurta, Anita K. Gandhi	3
6	Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma 2022 ·Blood ·Naser Ansari‐Pour, Mehmet Samur, Erin Flynt, Sarah Gooding, Fadi Towfic, Nicholas Stong, (unknown), Konstantinos Mavrommatis, Brian A. Walker, Gareth J. Morgan, Nikhil Munshi, Hervé Avet‐Loiseau, Anjan Thakurta	22
7	The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM 2022 ·Blood ·Nicholas Stong, (unknown), Fadi Towfic, Mehmet Samur, Amit Agarwal, Jill Corre, Erin Flynt, Nikhil Munshi, Hervé Avet‐Loiseau, Anjan Thakurta	21
8	Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma 2022 ·Blood ·Sarah Gooding, Naser Ansari‐Pour, (unknown), Kübra Karagoz, Ann Polonskaia, (unknown), (unknown), Korsuk Sirinukunwattana, Selina J Chavda, (unknown), Fadi Towfic, Erin Flynt, William E. Pierceall, Daniel Royston, Kwee Yong, Karthik Ramasamy, Paresh Vyas, Anjan Thakurta	13
9	Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways 2021 ·BMC Medical Genomics ·(unknown), Fadi Towfic, Erin Flynt, Nicholas Stong, In Sock Jang, Kai Wang, Matthew Trotter, Anjan Thakurta	8
10	Nanopore sequencing of single-cell transcriptomes with scCOLOR-seq 2021 ·Nature Biotechnology ·Martin Philpott, (unknown), Anjan Thakurta, Tom Brown, Tom Brown, Udo Oppermann, Adam P. Cribbs	61
11	Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma 2020 ·Clinical Cancer Research ·William E. Pierceall, Michael Amatangelo, Nizar J. Bahlis, David S. Siegel, Adeeb Rahman, Oliver Van Oekelen, Paola Neri, Mary H. Young, (unknown), Natalya V. Serbina, Samir Parekh, Amit Agarwal, Anjan Thakurta	27
12	Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients 2019 ·Blood ·Michael Amatangelo, Oliver Van Oekelen, Adeeb Rahman, Alessandro Laganà, Sarah Gooding, Hervé Avet‐Loiseau, Udo Oppermann, William E. Pierceall, Anjan Thakurta, Samir Parekh	9
13	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response 2017 ·Blood ·Michael Amatangelo, Lynn Quek, Alan H. Shih, Eytan M. Stein, Mikhail Roshal, Muriel D. David, Benoît Marteyn, Noushin Farnoud, Stéphane de Botton, Olivier Bernard, Bin Wu, Katharine Yen, Martin S. Tallman, Elli Papaemmanuil, Virginie Penard‐Lacronique, Anjan Thakurta, Paresh Vyas, Ross L. Levine	249
14	Correlative Analyses of Cereblon (CRBN), cMYC, IRF4, BLIMP1, and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) 2017 ·Blood ·Xiaozhong Qian, Meletios Α. Dimopoulos, Michael Amatangelo, Chad C. Bjorklund, Katja Weisel, Enrique M. Ocio, Xin Yu, Teresa Peluso, Lars Sternås, Mohamed H. Zaki, Philippe Moreau, Anjan Thakurta	1
15	Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed 2017 ·Blood ·David Siegel, Gary J. Schiller, Kevin Song, Richy Agajanian, (unknown), Hakan Kaya, Michaël Sébag, Christy Samaras, Ehsan Malek, Giampaolo Talamo, Christopher S. Seet, (unknown), Faiza Zafar, (unknown), Shankar Srinivasan, (unknown), Amit Agarwal, Anjan Thakurta, Nizar J. Bahlis	0
16	Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM) 2017 ·Blood ·Paola Neri, Ranjan Maity, (unknown), Peter Duggan, (unknown), Víctor H. Jiménez‐Zepeda, Jason Tay, Lawrence Boise, Anjan Thakurta, Nizar J. Bahlis	15
17	Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Included in the HOVON-87/Nmsg-18 Trial May be Associated with Longer PFS and OS 2017 ·Blood ·Ruth Wester, King H. Lam, Mark van Duin, Suzana S. Couto, Yan Ren, Maria Wang, Bronno van der Holt, Berna Beverloo, Heleen Visser-Wisselaar, Alex L. Nigg, (unknown), Anjan Thakurta, Annemiek Broyl, Sonja Zweegman, Pieter Sonneveld	1
18	Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 ^CRBN breakdown → 2013 ·British Journal of Haematology ·Anita K. Gandhi, Jian Kang, Courtney G. Havens, Thomas A. Conklin, Yuhong Ning, Lei Wu, Takumi Ito, Hideki Ando, Michelle F. Waldman, Anjan Thakurta, Anke Klippel, Hiroshi Handa, Thomas O. Daniel, Peter Schäfer, Rajesh Chopra	457
19	Homolog of BRCA2‐interacting Dss1p and Uap56p link Mlo3p and Rae1p for mRNA export in fission yeast 2005 ·The EMBO Journal ·Anjan Thakurta, (unknown), Jin Ho Yoon, Libor Kozák, Ravi Dhar	40
20	Crp79p, Like Mex67p, Is an Auxiliary mRNA Export Factor in Schizosaccharomyces pombe 2002 ·Molecular Biology of the Cell ·Anjan Thakurta, William Whalen, Jin Ho Yoon, (unknown), Libor Kozák, Craig C. Whiteford, Dona C. Love, John A. Hanover, Ravi Dhar	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact